The new site has an extended section highlighting the stories of patients whose lives were saved by ABIOMED's BVS 5000 and AB5000 systems. Additional enhancements to the site have been planned for this quarter, including the addition of online learning tools for clinical staff. Designed to improve outcomes, these tools will include interactive courses available to clinical staff for continuing education credits. In addition, the site will have specific content directed at nurses, surgeons, perfusionists and cardiologists offering protocols from top centers, recent journal articles, and a searchable "Ask the Expert" bulletin board where professionals can share information.

"We have completely rebuilt our web site in order to provide a comprehensive source of information on our product offerings in mechanical circulatory support," commented Michael R. Minogue, CEO and President of ABIOMED. "We understand that education is a critical element to supporting positive outcomes and saving lives. As a result, we will be continually adding new tools and resources in order to share best practices with our entire installed base."

Numerous studies and ABIOMED's own clinical database show that there are a series of best practices that influence survival rates for patients on ventricular assist devices, including early implantation and time on support. At the top 20 percent of centers in the Company's installed base, the survival rate is greater than 50 percent. This year, ABIOMED has rolled out a new support program focused on providing customers educational tools necessary to help ensure the best possible outcomes.

ABOUT ABIOMED
Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced "AB'-EE-O-MED") is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. ABIOMED currently manufactures and sells the AB5000™ Circulatory Support System and the BVS® 5000 Biventricular Support System for the temporary support of all patients with failing but potentially recoverable hearts. In Europe, ABIOMED offers the IMPELLA® RECOVER® minimally invasive cardiovascular support systems under CE Mark approval. The IMPELLA products are not yet available for sale in the United States. The Company's AbioCor® Implantable Replacement Heart was the subject of an initial clinical trial under an Investigational Device Exemption from the United States Food and Drug Administration. The AbioCor has not been approved for commercial distribution, and is not available for use or sale outside of the initial clinical trial. For additional information please visit: www.abiomed.com.

Contacts:
Liza Heapes
ABIOMED, INC.
Media Relations
(978) 646-1668
mediarelations@abiomed.com

Daniel Sutherby
ABIOMED, INC.
Chief Financial Officer
(978) 646-1812
ir@abiomed.com

FORWARD-LOOKING STATEMENTS
This Release contains forward-looking statements, including statements regarding development of ABIOMED's existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.